FDA approves Cobenfy: A breakthrough Schizophrenia treatment after decades

The US FDA has approved Bristol Myers Squibb’s new oral medicine, Cobenfy, for treating schizophrenia in adults. This approval introduces a novel pharmacological approach after more than 30 years. The drug will be available by late October at $1,850 per month before insurance and rebates. Clinical trials have shown significant improvement in symptoms compared to a placebo.